Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1–4N2–3M0 Nasopharyngeal Carcinoma (NPC)

A. W. Lee, W.H. Lau, Stewart Y. Tung, Daniel T. T. Chua, Rick Chappell, Lisa L. P. Siu, James Siu Ki Lau, S. C. K. Law, Lu Xu

Journal of Clinical Oncology · 2004 · 13 citations · 0 references

Concepts

Abstract

5506 Background: Concurrent chemoradiotherapy (CRT) has been widely advocated as the standard treatment for advanced NPC, since the Intergroup Study 0099 showed significant survival benefit by adding concurrent/adjuvant chemotherapy. However, there are serious concerns about the exact magnitude of benefit and lack of data on late toxicity. Methods: Patients with non-keratinizing NPC staged T1–4N2–3M0 were randomized in equal proportions to RT alone or CRT. The patients were stratified by center, T-stage, and N-stage. Both arms used the same RT technique and dose in line with the policy adopted by individual centers, all patients were treated with conventional fractionation to a total dose >= 66 Gy. Those in the CRT arm were given cisplatin 100 mg/m2 IV on Day 1, 22, 43, followed by cisplatin 80 mg/m2 IV and 5-fluorouracil 1000 mg/m2/d for 96 hr starting on Days 71, 99 and 127. The primary endpoint is progression-free survival (PFS) defined as the time to first failure at any site or death due to any cause. The protocol specified analyses to be performed shortly after completion of accrual and with complete 5-year follow-up. Secondary end-points include overall survival (OS), failure-free rates (FFR), and toxicities grade >=3. To achieve 80% power for detecting a 15% difference in PFS, target accrual is 340 patients. Results: From March 1999 to January 2004, 348 patients have been accrued: 176 were randomized to RT and 172 to CRT. The median follow-up was 25 months. The 2 arms were well-balanced in all prognostic factors and RT parameters. The chemotherapy-related toxicity rate in the CRT arm was 58% (32% being leukopenia). In addition, the CRT arm had a higher incidence of acute mucositis (63% v 46%, p = 0.01). The treatment effectiveness and late toxicity rates were listed in the attached Table. Significant differences thus far observed were loco-regional control and late toxicity. Fatal toxicities occurred in 2 patients from the CRT arm. Conclusions: This preliminary report shows that chemoradiotherapy could achieve significant improvement for locoregional control, but not for distant control and overall survival. The gain in PFS did not reach statistical significance. Chemoradiotherapy induced significantly higher incidence of toxicities (both acute and late). Longer follow-up is needed to confirm the current findings. No significant financial relationships to disclose.